Do Polynucleotide Skin Boosters Work? Rejuran & PDRN Evidence
By Dr. Mei Chen · Cosmetic Dermatologist & Senior Editor, The Exosome Edit
Updated Jul 2026Polynucleotide skin boosters — sold under names like Rejuran, Plinest, and Nucleofill — have gone from a Korean clinic secret to one of the most-requested injectables in the West. The pitch is seductive: short chains of purified salmon or trout DNA that "wake up" tired fibroblasts, rebuild collagen from the inside, and improve skin quality without adding filler-style volume. But does the clinical evidence hold up, or is this another regenerative-aesthetics story running ahead of its data?
Polynucleotide skin boosters — sold under names like Rejuran, Plinest, and Nucleofill — have gone from a Korean clinic secret to one of the most-requested injectables in the West. The pitch is seductive: short chains of purified salmon or trout DNA that "wake up" tired fibroblasts, rebuild collagen from the inside, and improve skin quality without adding filler-style volume. But does the clinical evidence hold up, or is this another regenerative-aesthetics story running ahead of its data?
The short version: polynucleotides have more human trial data than exosomes, and a real molecular mechanism backed by decades of wound-healing research. But most skin-rejuvenation trials are small, industry-adjacent, and short. The signal is promising and consistent. It is not the same as gold-standard, large randomized proof. This article walks through exactly what the studies show, where the gaps are, and how polynucleotides compare to the other regenerative treatments you've probably read about here.
Quick Answer
- Polynucleotides (PN/PDRN) have real, decades-deep wound-healing evidence.
- Skin-rejuvenation trials are small but consistently show texture and elasticity gains.
- It's an injectable — not a topical serum; needs a licensed injector.
- Better human data than exosomes, weaker than fillers or Botox.
What Are Polynucleotides (and How Do They Differ From PDRN)?
Polynucleotides (PN) and polydeoxyribonucleotides (PDRN) are short strands of DNA fragments, most commonly purified from the sperm or gonadal tissue of salmon and trout. That sounds strange, but the choice is deliberate: fish-derived DNA is highly similar to human DNA in structure while being low in immunogenicity after purification.
The terminology trips people up. PDRN generally refers to shorter, lower-molecular-weight fragments (roughly 50–2,000 base pairs) and is the form with the deepest pharmacology research — it's been studied as a wound-healing agent for years. PN usually refers to longer chains (higher molecular weight) marketed for aesthetic skin boosting. In practice, clinics and brands use the terms loosely and often interchangeably. Rejuran, the best-known brand, is a polynucleotide product.
The proposed mechanism has two parts. First, PDRN is thought to bind the adenosine A2A receptor on fibroblasts, triggering downstream signaling that promotes cell proliferation, collagen synthesis, and anti-inflammatory effects. Second, the fragments provide raw nucleotide building blocks via a "salvage pathway" that cells can reuse for their own DNA and tissue repair. A 2021 review in Pharmaceuticals details this dual mechanism and its role in accelerating impaired skin wound healing (Galeano et al., 2021, PMID 34832885).
This matters because it separates polynucleotides from dermal fillers. Hyaluronic acid fillers work by adding physical volume. Polynucleotides don't add meaningful volume — the claim is that they change how your own skin cells behave. Whether that translates to visible results is the whole question.
There's a third proposed effect worth mentioning: polynucleotides form a hydrophilic gel-like scaffold when injected. This matrix holds water and may act as a temporary lattice that fibroblasts migrate through, which is part of why some products blend polynucleotides with hyaluronic acid. So the mechanism is best understood as three overlapping actions — receptor signaling, nucleotide salvage, and physical scaffolding. All three are biologically plausible. How much each one contributes to a visible cosmetic result in healthy aging skin has not been cleanly separated in trials, which is a recurring theme in this field.
One more distinction people miss: molecular weight matters. Higher-molecular-weight PN chains behave more like a structural scaffold; lower-weight PDRN fragments are more bioactive at the receptor level. Different brands optimize for different ends of that spectrum, which is one reason results and marketing claims vary so much between products. When a clinic quotes a study, it's fair to ask whether that study used the same product they're about to inject into you.
Is a polynucleotide the same as a "skin booster"?
Roughly, yes. "Skin booster" is a marketing category, not a regulatory one. It covers injectables designed to improve skin quality (hydration, texture, elasticity) rather than sculpt or fill. Polynucleotides sit in this category alongside microdroplet hyaluronic acid products. The label tells you the goal, not the specific molecule — always ask what's actually in the syringe.
The Wound-Healing Evidence: The Strongest Data
Before polynucleotides became an aesthetic trend, PDRN was studied as a regenerative-medicine drug. This is the part of the evidence base that's genuinely strong, and it's why the mechanism isn't hand-waving.
The most cited human trial is a randomized controlled study of PDRN for chronic diabetic foot ulcers, published in the Journal of Clinical Endocrinology & Metabolism (Squadrito et al., 2014, PMID 24483158). Patients treated with PDRN showed significantly faster and more complete ulcer healing than placebo over the study period. Diabetic foot ulcers are notoriously hard to heal, so a positive signal there is meaningful.
| Evidence area | What it shows | Strength |
|---|---|---|
| Diabetic foot ulcer healing (RCT) | Faster complete healing vs placebo | Strong (randomized, clinical endpoint) |
| Impaired/chronic wound healing (review) | Consistent pro-repair, anti-inflammatory effects | Strong mechanistic + preclinical |
| A2A receptor mechanism | Plausible, reproducible in lab models | Well-characterized |
| Skin rejuvenation (aesthetics) | Texture/elasticity gains in small trials | Moderate, emerging |
The important caveat: healing an open ulcer and rejuvenating healthy aging skin are different jobs. Strong wound-healing data supports biological plausibility for skin rejuvenation. It does not prove the cosmetic benefit. Keep those two buckets separate — a lot of marketing blurs them on purpose.
What Does the Skin-Rejuvenation Evidence Actually Show?
Here's where you should calibrate your expectations. The aesthetic evidence is real but modest in scale.
The best summary is a 2025 systematic review in the Journal of Cosmetic Dermatology (Lampridou et al., 2025, PMID 39645667). It searched the major databases following PRISMA methodology and pooled the eligible human trials. The bottom line: across the included studies (covering roughly 219 patients receiving PN treatment), polynucleotides showed promising outcomes — reduced wrinkles, improved skin texture, and enhanced elasticity, with statistically significant results in several studies and moderate-to-high patient satisfaction throughout.
But the authors were explicit about the limits. Only nine studies met inclusion criteria. The trials varied widely in formulation, injection technique, outcome measures, and follow-up length, which made it hard to synthesize results or draw firm generalizable conclusions. That's a careful, honest read of the field — promising signal, thin and heterogeneous evidence base.
Some individual trials worth knowing:
| Study | Design | Key finding |
|---|---|---|
| Lee et al., 2022 (PMID 32248707) | Randomized, double-blind, split-face | PN vs HA for periocular rejuvenation; PN showed better roughness and pore improvement, comparable elasticity/hydration gains |
| Choi et al., 2025 (PMID 39313949) | Randomized, evaluator-blinded, matched-pair | PN vs polycaprolactone filler for crow's feet; both improved wrinkles, different profiles |
| Lampridou et al., 2025 (PMID 39645667) | Systematic review (9 studies, ~219 patients) | Consistent texture/elasticity/wrinkle improvement; evidence quality limited |
| PN HPT, 2024 (PMID 38371328) | Clinical evaluation, Asian skin | Reported skin regeneration and rejuvenation with high-purification PN |
| Ziade et al., 2026 (PMID 41689167) | Prospective observational | Periorbital rhytide improvement after PN injection series |
Notice the pattern. Several of the better-designed studies are split-face or matched-pair comparisons against hyaluronic acid — not against placebo. Comparing PN to another active treatment tells you they're roughly in the same ballpark. It doesn't isolate how much of the benefit is the polynucleotide versus the trauma of the needle itself (needling alone stimulates collagen). Placebo-controlled, adequately powered trials remain scarce.
It's also worth being honest about who funds and runs these trials. Much of the aesthetic polynucleotide literature comes from clinics and researchers in markets where the products are already commercially established, and industry involvement is common across cosmetic dermatology research generally. That doesn't invalidate the findings — split-face and blinded-evaluator designs are genuine methodological strengths. But it's a reason to weight independent replication heavily and to treat glowing single-study claims cautiously. The 2025 systematic review's measured language reflects exactly this: consistent positive signal, limited and heterogeneous evidence, cautious conclusions.
What the objective measurements actually captured
The better trials didn't rely only on patient satisfaction. Several used instrument-based endpoints — profilometry for skin roughness, cutometry for elasticity, and ultrasound or histology for dermal thickness. In the periocular split-face comparison (Lee et al., 2022, PMID 32248707), the polynucleotide side showed measurable gains in roughness and pore metrics, with elasticity and hydration improvements comparable to the hyaluronic acid control. Objective endpoints are more trustworthy than "patients were happy," and their inclusion is a point in the evidence's favor. The catch is that these are still short-term measurements on small samples, and instrument readings don't always track with what a patient sees in the mirror months later.
How long do polynucleotide results last?
Most clinics run a starter series of three to four sessions spaced two to four weeks apart, with results reported to last roughly six to twelve months before maintenance. That timeline comes from clinical practice and product guidance, not from large long-term trials — durability data past a year is limited. Treat the "6–12 months" figure as a reasonable working estimate, not a guarantee.
Polynucleotides vs Exosomes vs PRP vs Fillers
This is the comparison most people actually want, because these treatments get pitched interchangeably at the same clinics. They are not the same.
| Treatment | What it is | Human evidence | Volume effect | Regulatory clarity |
|---|---|---|---|---|
| Polynucleotides (PN/PDRN) | Purified fish-DNA fragments | Moderate (multiple small RCTs + strong wound data) | Minimal | CE-marked in EU; not FDA-cleared for skin rejuvenation in US |
| Exosomes | Cell-derived vesicles | Weak/emerging (mostly preclinical) | None | No FDA-approved products; active safety warnings |
| PRP | Your own concentrated platelets | Moderate, mixed (best for hair) | Minimal | Autologous; regulated as a procedure |
| HA fillers | Cross-linked hyaluronic acid | Strong (large RCTs, FDA-approved) | Substantial | FDA-approved |
Two honest takeaways. First, polynucleotides have meaningfully more human trial data than exosomes, which remain largely preclinical for skin rejuvenation. If you're choosing between the two on evidence alone, PN is the stronger bet. We break the exosome comparison down further in our salmon DNA PDRN vs exosomes skin booster showdown and in PRP vs exosomes.
Second, none of these regenerative treatments match the evidence base of established options. Hyaluronic acid fillers and botulinum toxin have large, FDA-approved, placebo-controlled trials behind them. Polynucleotides are promising and better-studied than the hype-heavy category around them — but "better than exosomes" is a low bar to clear.
Combining Polynucleotides With Other Treatments
In real clinics, polynucleotides are rarely used in isolation. The more interesting question is how they fit into a broader plan, and here the logic is more sound than the standalone hype.
Because polynucleotides target skin quality rather than volume or muscle movement, they slot cleanly next to treatments that do those other jobs. A common combination protocol looks like this:
| Pairing | Rationale | Evidence status |
|---|---|---|
| PN + hyaluronic acid filler | Filler restores volume; PN improves overlying skin quality | Complementary, mechanistically sensible |
| PN + botulinum toxin | Toxin softens dynamic lines; PN targets static skin texture | Complementary, widely practiced |
| PN + microneedling or energy devices | Devices create controlled injury; PN may support the repair phase | Plausible; recovery-support role, limited direct trials |
| PN + topical actives (retinoids, vitamin C, sunscreen) | Home routine drives ongoing collagen support and photoprotection | Strong for the topicals independently |
The most defensible framing: polynucleotides can be a quality-improving layer on top of a foundation of proven basics. They do not replace daily sunscreen, a retinoid, and antioxidant protection — the boring, best-evidenced anti-aging stack. If your topical routine is a mess, fixing that will likely do more for your skin than any injectable series. A skin booster is a supplement to good fundamentals, not a substitute for them.
One practical caution on stacking: piling multiple new procedures into a short window raises the odds of side effects and makes it impossible to tell what actually worked. Sensible clinics space and sequence treatments and change one variable at a time.
Topical Polynucleotides and PDRN Serums: A Reality Check
You've probably seen serums marketed with "PDRN" or "polynucleotide" on the label. Be skeptical here. The clinical evidence for polynucleotides comes almost entirely from injection, where the fragments are delivered into the dermis. DNA fragments are large molecules that don't readily penetrate an intact stratum corneum, so a leave-on serum is unlikely to deliver the same dermal exposure.
There may be a role for topical PDRN in specific contexts — post-procedure recovery, for instance, when the skin barrier is temporarily disrupted by microneedling or laser. But "topical polynucleotide serum = same benefit as Rejuran injections" is not supported. We cover this in detail in our topical PDRN skincare research review. If you want the injectable benefit, the evidence points to injection.
Safety, Side Effects, and Regulatory Status
Polynucleotides have a reassuring short-term safety profile in the trials to date. Because the DNA is highly purified and biocompatible, allergic reactions are uncommon (though not impossible — anyone with a documented fish or seafood allergy should flag it, even though purified PDRN carries little protein).
The most common side effects are what you'd expect from any injectable: redness, swelling, bruising, tenderness, and small bumps at injection sites that typically resolve within days. Serious adverse events are rare in the published literature, but the literature is small and short-term, so rare long-tail risks may be underreported.
Regulatory status is where you need to be careful, and it varies by country:
- Europe/UK/Asia: Many polynucleotide products (Rejuran, Plinest, Nucleofill) carry CE marks or local approvals as medical devices/injectables and are widely used in clinics.
- United States: As of 2026, injectable polynucleotide skin boosters like Rejuran are not FDA-approved or cleared for skin rejuvenation. Products used in US clinics may be imported or offered off-label, which shifts the safety and legal burden onto the provider. This is a genuine gray area — ask directly what's being injected and whether it's FDA-cleared.
For context on how the FDA treats this whole regenerative category: the agency's Public Safety Notification on Exosome Products states there are no FDA-approved exosome products and reports adverse events including infections tied to unapproved regenerative products (FDA, Public Safety Notification on Exosome Products). Polynucleotides are a distinct molecule with better data than exosomes, but the regulatory caution around the broader "regenerative aesthetics" market applies. If you want the full landscape, see our complete exosome skincare guide.
Who should be cautious or avoid it?
Skip or delay polynucleotide injections if you're pregnant or breastfeeding (no safety data), have an active skin infection at the site, have a known fish/seafood allergy, or have an autoimmune or bleeding disorder without clearing it with a physician first. As with any injectable, the injector's training matters more than the product — improper technique causes most complications.
Are Polynucleotides Worth It? An Honest Verdict
If you want a straight answer: polynucleotides are one of the more evidence-supported entries in the regenerative-aesthetics wave, but they are not a miracle and the data is still maturing.
Reasonable expectations, based on the trials:
- Best for: skin quality — texture, fine lines, elasticity, dullness, under-eye crepiness. Especially periocular skin, where several of the better studies focused.
- Not for: replacing filler for volume loss, or replacing Botox for dynamic wrinkles. Different tools, different jobs.
- Realistic result: subtle, cumulative improvement in skin quality over a series, not a dramatic overnight change.
The value question depends on price and alternatives in your area. A series of three to four sessions isn't cheap, and the honest comparison is against a well-formulated topical routine plus a proven in-office treatment like microneedling (which itself stimulates collagen and is often combined with these boosters — see our microneedling with exosomes cost and reviews for how add-ons stack up).
Our take: polynucleotides are a legitimate, defensible choice for skin-quality goals if you have a skilled injector and clear-eyed expectations. They're a better-evidenced pick than exosomes. But if someone promises dramatic, filler-like or laser-like results from a polynucleotide series, that's overselling what the science actually shows.
Frequently Asked Questions
Do polynucleotide skin boosters actually work? The evidence says: probably yes, modestly, for skin quality. Multiple small human trials and a 2025 systematic review show consistent improvements in texture, elasticity, and fine wrinkles. But the studies are small and often compare PN to another active treatment rather than placebo, so the effect size versus doing nothing isn't precisely established.
Are polynucleotides better than exosomes? On human evidence, yes. Polynucleotides have multiple published clinical trials and decades of wound-healing research behind the mechanism. Exosomes for skin rejuvenation remain mostly preclinical, with no FDA-approved products and active safety warnings around the category.
How many sessions do I need and how long do results last? Typical protocols use three to four sessions spaced two to four weeks apart, with reported results lasting six to twelve months before maintenance. These figures come from clinical practice and product guidance; long-term trial data is limited.
Is Rejuran FDA-approved in the US? No. As of 2026, injectable polynucleotide products like Rejuran are not FDA-approved or cleared for skin rejuvenation in the United States. They're widely approved in Korea, Europe, and elsewhere. In the US they may be used off-label or imported — ask your provider directly what they're injecting.
Can I get the benefits from a polynucleotide or PDRN serum instead of injections? Unlikely to the same degree. The clinical benefit is documented for injected polynucleotides delivered into the dermis. Topical DNA fragments don't penetrate intact skin well, so serums shouldn't be expected to replicate injection results. There may be a supportive role in post-procedure recovery.
Medical Disclaimer
This article is for educational purposes only and is not medical advice. Polynucleotide and PDRN injections are cosmetic medical procedures that carry risks and should only be performed by a licensed, qualified provider after an in-person consultation. Information here does not establish a provider-patient relationship. Regulatory status, product availability, and safety data change over time and vary by country. Anyone considering these treatments — especially those who are pregnant, breastfeeding, immunocompromised, or managing a chronic condition — should consult a board-certified dermatologist or physician before proceeding. Do not use this content to diagnose or treat any condition.
Sources
- Galeano M, et al. Polydeoxyribonucleotide: A Promising Biological Platform to Accelerate Impaired Skin Wound Healing. Pharmaceuticals (Basel). 2021. PMID: 34832885. https://pubmed.ncbi.nlm.nih.gov/34832885/
- Squadrito F, et al. The effect of PDRN, an adenosine receptor A2A agonist, on the healing of chronic diabetic foot ulcers: results of a clinical trial. J Clin Endocrinol Metab. 2014 May. PMID: 24483158. https://pubmed.ncbi.nlm.nih.gov/24483158/
- Lampridou S, et al. The Effectiveness of Polynucleotides in Esthetic Medicine: A Systematic Review. J Cosmet Dermatol. 2025 Feb. PMID: 39645667. https://pubmed.ncbi.nlm.nih.gov/39645667/
- Lee YJ, et al. Comparison of the effects of polynucleotide and hyaluronic acid fillers on periocular rejuvenation: a randomized, double-blind, split-face trial. J Dermatolog Treat. 2022 Feb. PMID: 32248707. https://pubmed.ncbi.nlm.nih.gov/32248707/
- Choi SY, et al. A Randomized, Participant- and Evaluator-Blinded, Matched-Pair, Prospective Study Comparing the Safety and Efficacy Between Polycaprolactone and Polynucleotide Fillers in the Correction of Crow's Feet. J Cosmet Dermatol. 2025 Jan. PMID: 39313949. https://pubmed.ncbi.nlm.nih.gov/39313949/
- Polynucleotides HPT for Asian Skin Regeneration and Rejuvenation. Clin Cosmet Investig Dermatol. 2024. PMID: 38371328. https://pubmed.ncbi.nlm.nih.gov/38371328/
- Ziade G, et al. Prospective Observational Study of Polynucleotide Injections for Periorbital Rhytides. J Cosmet Dermatol. 2026 Feb. PMID: 41689167. https://pubmed.ncbi.nlm.nih.gov/41689167/
- U.S. Food and Drug Administration. Public Safety Notification on Exosome Products. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-products
— The Exosome Edit Team